8 Significant investment in commercial manufacturing has positioned Kodiak well for potential launch of multiple ABC ® products into large and growing markets URSUS, a premium commercial manufacturing facility dedicated to the manufacture of Kodiak’s ABC ® medicines • Custom designed for large scale premium manufacturing of complex antibody conjugate biotherapies • Mechanical completion in 1H2022; commissioned as a cGMP facility for commercial supply in Jan 2023 • Successful cGMP manufacture and release commercial scale tarcocimab commercial formulation in Nov 2023 • BLA-facing commercial-scale validation batches were manufactured and released in 2025 for antibody, biopolymer and bioconjugate